TP53 in hematological cancer: low incidence of mutations with significant clinical relevance.

Abstract excerpt

Inactivation of the wild-type p53 gene (TP53) by various genetic alterations is a major event in human tumorigenesis. More than 60% of human primary tumors exhibit a mutation in the p53 gene. Hematological malignancies present a rather low incidence of genetic alterations in this gene (10-20%). Nevertheless, epidemiological studies of the hematological malignancies indicate that the prognosis of patients with a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Apoptosis
• Share to Cancer-related Molecular Pathways
• Share to Chromosome Aberrations